The United States market has been flat over the last week but is up 24% over the past year, with earnings forecast to grow by 15% annually. In this context of robust growth expectations, identifying ...

RBC Capital raised the firm’s price target on Exelixis (EXEL) to $38 from $34 and keeps an Outperform rating on the shares. Zanzalintinib ...

The global phosphoinositide 3-kinase inhibitor market is poised to witness significant growth, projected to expand at a robust CAGR of 5.61% during the forecast period from 2019 to 2026.

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

Principal Financial Group Inc. lessened its holdings in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 31.6% during the third ...

Brookline Capital Markets analysts initiated coverage on Exelixis (NASDAQ:EXEL) with a Buy rating and a $40 price target, ...

Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase III for Laryngeal Cancer.

Another notable valuation metric for EXEL is its P/B ratio of 4.24. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total ...

Investment analysts at Brookline Capital Management assumed coverage on shares of Exelixis (NASDAQ:EXEL – Get Free Report) in ...

Exelixis Inc (EXEL) stock saw a modest uptick, ending the day at $33.48 which represents a slight increase of $0.19 or 0.57% from the prior close of $33.29. The stock opened at $33.46 and touched a ...

Brookline Capital Markets initiated coverage of Exelixis (EXEL) with a buy rating, highlighting the company's revenue ...